Company Profile
BioAtla, Inc. Stock Price, News & Catalysts
- Ticker:
- BCAB
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.18 USD (0.00%)
Close
Last updated: August 21, 2026
5.85M USD
Market cap
Why the stock is moving
As of Aug 21, 2026, BCAB was little changed and closed at $3.18. No new same-company headline was identified in the current news window.
Company overview
Conditionally Active Biologics
BioAtla develops antibodies engineered to bind preferentially under conditions found in the tumor microenvironment. The CAB platform uses factors such as acidic pH to reduce target binding in normal tissue and potentially limit on-target, off-tumor toxicity.
BA3182
BA3182 is a conditionally active EpCAM and CD3 bispecific T-cell engager in Phase 1 development for advanced adenocarcinomas. Both binding arms are designed to activate preferentially within tumors.
Antibody-Drug Conjugates
The clinical ADC portfolio includes ozuriftamab vedotin against ROR2 and mecbotamab vedotin against AXL. Programs have been studied in oropharyngeal cancer, sarcoma and KRAS-mutant lung cancer.
Broader CAB Pipeline
Evalstotug is a conditionally active CTLA-4 antibody, while preclinical assets target Nectin-4, B7H4, B7H3, EGFR and Trop2. BioAtla is evaluating strategic transactions and may alter the pace or scope of these programs while preserving capital.
Future catalysts
- BioAtla’s catalysts are conditional-activation antibodies and any oncology update that shows the platform can still differentiate. The company remains data-sensitive because the platform story is not yet fully proven.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of BioAtla, Inc. (BCAB)?
BioAtla, Inc. (BCAB) most recently closed at 3.18 USD, a 0.00% move versus the previous session.
What is the market cap of BioAtla, Inc. (BCAB)?
BioAtla, Inc. currently has a market capitalization of 5.85M USD on BioPharmSignal.
What does BioAtla, Inc. do?
Conditionally Active Biologics BioAtla develops antibodies engineered to bind preferentially under conditions found in the tumor microenvironment. The CAB platform uses factors such as acidic pH to reduce target binding in normal tissue and potentially limit on-target, off-tumor toxicity. BA3182 BA3182 is a conditionally active EpCAM and CD3 bispecific...
On which exchange is BCAB stock listed?
BioAtla, Inc. (BCAB) is associated with NASDAQ, United States, Biopharma.
What is CTLA-4?
Broader CAB Pipeline Evalstotug is a conditionally active CTLA-4 antibody, while preclinical assets target Nectin-4, B7H4, B7H3, EGFR and Trop2.
Which conditions is BioAtla, Inc. targeting with CTLA-4?
BioAtla, Inc. is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does BioAtla, Inc. describe recent progress with CTLA-4?
BioAtla’s catalysts are conditional-activation antibodies and any oncology update that shows the platform can still differentiate. The company remains data-sensitive because the platform story is not yet fully proven.
What is ozuriftamab?
Antibody-Drug Conjugates The clinical ADC portfolio includes ozuriftamab vedotin against ROR2 and mecbotamab vedotin against AXL.